Annovis Bio, Inc.
ANVS
$1.24
-$0.06-4.62%
NYSE
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 5.66M | 4.40M | 4.48M | 5.26M | 5.82M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 49.43M | 41.32M | 29.70M | 26.72M | 23.68M |
| Operating Income | -49.43M | -41.32M | -29.70M | -26.72M | -23.68M |
| Income Before Tax | -49.52M | -40.92M | -28.85M | -24.88M | -30.26M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -49.52 | -40.92 | -28.85 | -24.88 | -30.26 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -49.52M | -40.92M | -28.85M | -24.88M | -30.26M |
| EBIT | -49.43M | -41.32M | -29.70M | -26.72M | -23.68M |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -1.78 | -1.70 | -1.39 | -1.43 | -2.04 |
| Normalized Basic EPS | -1.11 | -1.06 | -0.87 | -0.89 | -1.27 |
| EPS Diluted | -1.79 | -1.71 | -1.39 | -1.49 | -2.09 |
| Normalized Diluted EPS | -1.11 | -1.06 | -0.87 | -0.89 | -1.27 |
| Average Basic Shares Outstanding | 110.63M | 92.60M | 82.18M | 70.40M | 63.69M |
| Average Diluted Shares Outstanding | 110.63M | 92.60M | 82.18M | 70.40M | 63.69M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |